Cardio Diagnostics Holdings Inc. (NASDAQ: CDIO) is addressing a critical blind spot in coronary heart disease (CHD) detection with molecular precision tools that go beyond traditional risk assessments. According to the company, approximately 50% of individuals with CHD do not present with conventional risk factors, and standard risk calculators have an average sensitivity of only 39%. This means many people who appear healthy may still develop CHD and suffer preventable cardiac events such as heart attacks.
For decades, cardiovascular risk assessment has relied on a checklist of factors including cholesterol levels, blood pressure, smoking history, diabetes status, family history, and weight. While these factors are useful, they were never designed to capture the full biological picture of how heart disease develops. The consequences of this gap are significant: CHD remains the leading cause of death in the United States, yet a large portion of cases are preventable if detected early.
Cardio Diagnostics has developed clinical tests rooted in epigenetics and genetics—fields that examine how genes are expressed and regulated at the molecular level. These tests aim to provide a more comprehensive understanding of an individual's risk by looking beyond traditional metrics. The company's approach could transform early detection, potentially reducing the number of undiagnosed cases and preventing heart attacks.
For investors, the latest news and updates regarding CDIO are available in the company’s newsroom at https://ibn.fm/CDIO. The implications of this technology are far-reaching: if adopted widely, it could change how healthcare providers screen for heart disease, shifting from a one-size-fits-all checklist to personalized molecular profiling. This could lead to earlier interventions, better patient outcomes, and reduced healthcare costs associated with treating advanced CHD.
The news matters because it highlights a fundamental flaw in current cardiovascular screening methods and offers a potential solution. By bringing molecular precision to a blind spot in CHD detection, Cardio Diagnostics may help close the gap for the millions of Americans at risk. The company's focus on epigenetics and genetics represents a forward-looking approach that could reshape preventive cardiology.
